FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to haematology, and can be used for hormonal and radiation preparation to the following radiation chemotherapy in the treatment of patients with chronic lymphocytic leukaemia. For this purpose prednisolone is introduced in a dose of 0.9-1.1 mg/kg of weight per day. Exposure to radiation in the doses and regimens, conventional for the treatment of lymphoid tumours of a low-degree of malignancy is also carried out in the term from 72 to 168 hours after the beginning of prednisolone introduction. After obtaining 2/3-3/4 of the total dose of the radiation impact, reduction of the dose of introduced prednisolone is realised with its cancellation by the end of the radiation impact. Exposed to radiation are: involved into the leukemic process lymphatic organs from the group: lymph nodes, tonsils, spleen and liver.;EFFECT: method ensures an increased efficiency of chemotherapeutical programmes due to the preliminary impact, making it possible to reduce the involvement of organs into the leukemic process, increased sensitivity of leukemic lymphocytes to the following chemotherapeutic impact , with the reduction of a probability of development of complications, for instance, such as febrile neutropenia.;5 ex
展开▼
